1	Heparin-steroid	Heparin-steroid	B-NP	JJ	O	2	NMOD	0
2	conjugates	conjugate	I-NP	NNS	O	6	NMOD	0
3	:	:	O	:	O	2	P	0
4	new	new	B-NP	JJ	O	6	NMOD	0
5	angiogenesis	angiogenesis	I-NP	NN	O	6	NMOD	3	angiogenesis
6	inhibitors	inhibitor	I-NP	NNS	O	0	ROOT	0
7	with	with	B-PP	IN	O	6	NMOD	0
8	antitumor	antitumor	B-NP	JJ	O	9	NMOD	0
9	activity	activity	I-NP	NN	O	7	PMOD	18	activity
10	in	in	B-PP	IN	O	9	NMOD	0
11	mice	mouse	B-NP	NNS	O	10	PMOD	0
12	.	.	O	.	O	6	P	0

1	Inhibitors	Inhibitor	B-NP	NNS	O	4	SUB	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	angiogenesis	angiogenesis	B-NP	NN	O	2	PMOD	3	angiogenesis
4	hold	hold	B-VP	VBP	O	0	ROOT	0
5	potential	potential	B-NP	NN	O	4	OBJ	0
6	in	in	B-PP	IN	O	5	NMOD	0
7	the	the	B-NP	DT	O	8	NMOD	0
8	treatment	treatment	I-NP	NN	O	6	PMOD	19	treatment
9	of	of	B-PP	IN	O	8	NMOD	0
10	cancer	cancer	B-NP	NN	O	13	NMOD	0
11	and	and	O	CC	O	13	NMOD	0
12	other	other	B-NP	JJ	O	13	NMOD	0
13	diseases	disease	I-NP	NNS	O	9	PMOD	0
14	where	where	B-ADVP	WRB	O	13	NMOD	0
15	the	the	B-NP	DT	O	16	NMOD	0
16	disease	disease	I-NP	NN	O	17	SUB	0
17	is	be	B-VP	VBZ	O	14	SBAR	0
18	caused	cause	I-VP	VBN	O	17	VC	0
19	or	or	I-VP	CC	O	18	VMOD	0
20	maintained	maintain	I-VP	VBN	O	18	VMOD	0
21	by	by	B-PP	IN	O	20	VMOD	0
22	the	the	B-NP	DT	O	24	NMOD	0
23	inappropriate	inappropriate	I-NP	JJ	O	24	NMOD	0
24	growth	growth	I-NP	NN	O	21	PMOD	4	growth
25	of	of	B-PP	IN	O	24	NMOD	0
26	blood	blood	B-NP	NN	O	27	NMOD	0
27	vessels	vessel	I-NP	NNS	O	25	PMOD	0
28	.	.	O	.	O	4	P	0

1	In	In	B-PP	IN	O	11	VMOD	0
2	the	the	B-NP	DT	O	4	NMOD	0
3	present	present	I-NP	JJ	O	4	NMOD	0
4	study	study	I-NP	NN	O	1	PMOD	0
5	,	,	O	,	O	11	P	0
6	a	a	B-NP	DT	O	8	NMOD	0
7	novel	novel	I-NP	JJ	O	8	NMOD	0
8	inhibitor	inhibitor	I-NP	NN	O	11	SUB	0
9	of	of	B-PP	IN	O	8	NMOD	0
10	angiogenesis	angiogenesis	B-NP	NN	O	9	PMOD	3	angiogenesis
11	was	be	B-VP	VBD	O	0	ROOT	0
12	synthesized	synthesize	I-VP	VBN	O	11	VC	0
13	by	by	B-PP	IN	O	12	VMOD	0
14	covalently	covalently	B-VP	RB	O	15	VMOD	0
15	linking	link	I-VP	VBG	O	13	PMOD	0
16	a	a	B-NP	DT	O	18	NMOD	0
17	nonanticoagulating	nonanticoagulating	I-NP	JJ	O	18	NMOD	0
18	derivative	derivative	I-NP	NN	O	15	OBJ	0
19	of	of	B-PP	IN	O	18	NMOD	0
20	heparin	heparin	B-NP	NN	O	19	PMOD	0
21	,	,	O	,	O	11	VMOD	0
22	heparin	heparin	B-NP	NN	O	24	NMOD	0
23	adipic	adipic	I-NP	JJ	O	24	NMOD	0
24	hydrazide	hydrazide	I-NP	NN	O	21	OBJ	0
25	(	(	O	(	O	27	DEP	0
26	HAH	HAH	B-NP	NN	B-protein	27	DEP	0
27	)	)	O	)	O	24	NMOD	0
28	,	,	O	,	O	24	P	0
29	by	by	B-PP	IN	O	24	NMOD	0
30	an	an	B-NP	DT	O	32	NMOD	0
31	acid-labile	acid-labile	I-NP	JJ	O	32	NMOD	0
32	bond	bond	I-NP	NN	O	29	PMOD	0
33	to	to	B-PP	TO	O	32	NMOD	0
34	the	the	B-NP	DT	O	36	NMOD	0
35	antiangiogenic	antiangiogenic	I-NP	JJ	O	36	NMOD	3	angiogenic
36	steroid	steroid	I-NP	NN	O	38	NMOD	0
37	,	,	O	,	O	38	P	0
38	cortisol	cortisol	B-NP	NN	O	33	PMOD	0
39	.	.	O	.	O	11	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	rationale	rationale	I-NP	NN	O	3	SUB	0
3	was	be	B-VP	VBD	O	0	ROOT	0
4	that	that	B-SBAR	IN	O	3	PRD	0
5	the	the	B-NP	DT	O	7	NMOD	0
6	heparin	heparin	I-NP	NN	O	7	NMOD	0
7	derivative	derivative	I-NP	NN	O	19	SUB	0
8	,	,	O	,	O	7	P	0
9	which	which	B-NP	WDT	O	7	NMOD	0
10	binds	bind	B-VP	VBZ	O	9	SBAR	15	binds
11	to	to	B-PP	TO	O	10	VMOD	0
12	sulfated	sulfate	B-NP	VBN	O	14	NMOD	0
13	polyanion	polyanion	I-NP	NN	B-protein	14	NMOD	0
14	receptors	receptor	I-NP	NNS	I-protein	11	PMOD	0
15	on	on	B-PP	IN	O	14	NMOD	0
16	endothelial	endothelial	B-NP	JJ	B-cell_type	17	NMOD	0
17	cells	cell	I-NP	NNS	I-cell_type	15	PMOD	0
18	,	,	O	,	O	7	P	0
19	should	should	B-VP	MD	O	4	SBAR	0
20	concentrate	concentrate	I-VP	VB	O	19	VC	0
21	the	the	B-NP	DT	O	22	NMOD	0
22	steroid	steroid	I-NP	NN	O	20	OBJ	0
23	on	on	B-PP	IN	O	22	NMOD	0
24	the	the	B-NP	DT	O	25	NMOD	0
25	surface	surface	I-NP	NN	O	23	PMOD	0
26	of	of	B-PP	IN	O	25	NMOD	0
27	vascular	vascular	B-NP	JJ	B-cell_type	29	NMOD	0
28	endothelial	endothelial	I-NP	JJ	I-cell_type	29	NMOD	0
29	cells	cell	I-NP	NNS	I-cell_type	26	PMOD	0
30	.	.	O	.	O	3	P	0

1	Endocytosis	Endocytosis	B-NP	NN	O	18	SUB	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	the	the	B-NP	DT	O	6	NMOD	0
4	conjugate	conjugate	I-NP	NN	O	6	NMOD	0
5	and	and	I-NP	CC	O	6	NMOD	0
6	decomposition	decomposition	I-NP	NN	O	2	PMOD	0
7	of	of	B-PP	IN	O	6	NMOD	0
8	the	the	B-NP	DT	O	10	NMOD	0
9	acid-labile	acid-labile	I-NP	JJ	O	10	NMOD	0
10	linkage	linkage	I-NP	NN	O	7	PMOD	0
11	inside	inside	B-PP	IN	O	1	NMOD	0
12	lysosomes	lysosome	B-NP	NNS	O	17	NMOD	0
13	and	and	O	CC	O	17	NMOD	0
14	other	other	B-NP	JJ	O	17	NMOD	0
15	acidic	acidic	I-NP	JJ	O	17	NMOD	0
16	intracellular	intracellular	I-NP	JJ	O	17	NMOD	0
17	compartments	compartment	I-NP	NNS	O	11	PMOD	0
18	should	should	B-VP	MD	O	0	ROOT	0
19	then	then	I-VP	RB	O	18	VMOD	0
20	lead	lead	I-VP	VB	O	18	VC	0
21	to	to	B-PP	TO	O	20	VMOD	0
22	release	release	B-NP	NN	O	21	PMOD	14	release
23	of	of	B-PP	IN	O	22	NMOD	0
24	the	the	B-NP	DT	O	27	NMOD	0
25	cortisol	cortisol	I-NP	NN	O	27	NMOD	0
26	and	and	I-NP	CC	O	27	NMOD	0
27	expression	expression	I-NP	NN	O	23	PMOD	0
28	of	of	B-PP	IN	O	27	NMOD	0
29	its	its	B-NP	PRP$	O	31	NMOD	0
30	antiproliferative	antiproliferative	I-NP	JJ	O	31	NMOD	0
31	activity	activity	I-NP	NN	O	28	PMOD	0
32	.	.	O	.	O	18	P	0

1	Analysis	Analysis	B-NP	NN	O	7	SUB	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	the	the	B-NP	DT	O	4	NMOD	0
4	stability	stability	I-NP	NN	O	2	PMOD	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	HAH-cortisol	HAH-cortisol	B-NP	NN	O	5	PMOD	0
7	showed	show	B-VP	VBD	O	0	ROOT	0
8	that	that	B-SBAR	IN	O	7	VMOD	0
9	it	it	B-NP	PRP	O	10	SUB	0
10	was	be	B-VP	VBD	O	8	SBAR	0
11	stable	stable	B-ADJP	JJ	O	10	PRD	0
12	at	at	B-PP	IN	O	11	AMOD	0
13	pH	pH	B-NP	NN	O	12	PMOD	0
14	7.4	7.4	I-NP	CD	O	13	NMOD	0
15	and	and	O	CC	O	10	VMOD	0
16	broke	break	B-VP	VBD	O	10	VMOD	0
17	down	down	B-PRT	RP	O	16	VMOD	0
18	rapidly	rapidly	B-ADVP	RB	O	16	VMOD	0
19	(	(	O	(	O	23	DEP	0
20	t1/2	t1/2	B-NP	NN	O	22	NMOD	0
21	15	15	I-NP	CD	O	22	NMOD	0
22	min	min	I-NP	NN	O	23	DEP	0
23	)	)	O	)	O	18	AMOD	0
24	at	at	B-PP	IN	O	16	VMOD	0
25	pH	pH	B-NP	NN	O	24	PMOD	0
26	4.8	4.8	I-NP	CD	O	25	NMOD	0
27	at	at	B-PP	IN	O	16	VMOD	0
28	37	37	B-NP	CD	O	30	NMOD	0
29	degrees	degree	I-NP	NNS	O	30	NMOD	0
30	C	C	B-ADJP	JJ	O	27	PMOD	0
31	.	.	O	.	O	7	P	0

1	Treatment	Treatment	B-NP	NN	O	22	SUB	19	Treatment
2	of	of	B-PP	IN	O	1	NMOD	0
3	murine	murine	B-NP	JJ	B-cell_line	7	NMOD	0
4	pulmonary	pulmonary	I-NP	JJ	I-cell_line	7	NMOD	0
5	capillary	capillary	I-NP	JJ	I-cell_line	7	NMOD	0
6	endothelial	endothelial	I-NP	JJ	I-cell_line	7	NMOD	0
7	cells	cell	I-NP	NNS	I-cell_line	2	PMOD	0
8	with	with	B-PP	IN	O	1	NMOD	0
9	HAH-cortisol	HAH-cortisol	B-NP	NN	O	8	PMOD	0
10	at	at	B-PP	IN	O	1	NMOD	0
11	10	10	B-NP	CD	O	15	NMOD	0
12	(	(	O	(	O	14	DEP	0
13	-5	-5	B-NP	CD	O	14	DEP	0
14	)	)	O	)	O	11	NMOD	0
15	M	M	B-NP	NN	O	10	PMOD	0
16	(	(	O	(	O	21	DEP	0
17	with	with	B-PP	IN	O	21	DEP	0
18	respect	respect	B-NP	NN	O	17	PMOD	0
19	to	to	B-PP	TO	O	18	NMOD	0
20	cortisol	cortisol	B-NP	NN	O	19	PMOD	0
21	)	)	O	)	O	15	NMOD	0
22	suppressed	suppress	B-VP	VBD	O	0	ROOT	0
23	their	their	B-NP	PRP$	O	25	NMOD	0
24	DNA	DNA	I-NP	NN	O	25	NMOD	0
25	synthesis	synthesis	I-NP	NN	O	22	OBJ	0
26	by	by	B-PP	IN	O	22	VMOD	0
27	50	50	B-NP	CD	O	28	NMOD	0
28	%	%	I-NP	NN	O	26	PMOD	0
29	and	and	O	CC	O	22	VMOD	0
30	inhibited	inhibit	B-VP	VBD	O	22	VMOD	18	inhibited
31	their	their	B-NP	PRP$	O	32	NMOD	0
32	migration	migration	I-NP	NN	O	30	OBJ	14	migration
33	into	into	B-PP	IN	O	32	NMOD	0
34	wounded	wounded	B-NP	JJ	O	35	NMOD	0
35	areas	area	I-NP	NNS	O	33	PMOD	0
36	of	of	B-PP	IN	O	35	NMOD	0
37	confluent	confluent	B-NP	JJ	O	38	NMOD	0
38	monolayers	monolayer	I-NP	NNS	O	36	PMOD	0
39	.	.	O	.	O	22	P	0

1	HAH-cortisol	HAH-cortisol	B-NP	NN	O	14	SUB	0
2	at	at	B-PP	IN	O	1	NMOD	0
3	10	10	B-NP	CD	O	7	NMOD	0
4	(	(	O	(	O	6	DEP	0
5	-4	-4	B-NP	CD	O	6	DEP	0
6	)	)	O	)	O	3	NMOD	0
7	M	M	B-NP	NN	O	2	PMOD	0
8	(	(	O	(	O	7	NMOD	0
9	with	with	B-PP	IN	O	7	NMOD	0
10	respect	respect	B-NP	NN	O	9	PMOD	0
11	to	to	B-PP	TO	O	10	NMOD	0
12	cortisol	cortisol	B-NP	NN	O	11	PMOD	0
13	)	)	O	)	O	7	NMOD	0
14	did	do	B-VP	VBD	O	0	ROOT	0
15	not	not	I-VP	RB	O	14	VMOD	0
16	suppress	suppress	I-VP	VB	O	14	VC	0
17	the	the	B-NP	DT	O	19	NMOD	0
18	DNA	DNA	I-NP	NN	O	19	NMOD	0
19	synthesis	synthesis	I-NP	NN	O	16	OBJ	0
20	of	of	B-PP	IN	O	19	NMOD	0
21	Lewis	Lewis	B-NP	NNP	O	24	NMOD	0
22	lung	lung	I-NP	NN	B-cell_type	24	NMOD	0
23	carcinoma	carcinoma	I-NP	NN	I-cell_type	24	NMOD	0
24	cells	cell	I-NP	NNS	I-cell_type	20	PMOD	0
25	.	.	O	.	O	14	P	0

1	Daily	Daily	B-NP	JJ	O	2	NMOD	0
2	i.p	i.p	I-NP	NN	O	0	ROOT	0
3	.	.	O	.	O	2	P	0

1	injections	injection	B-NP	NNS	O	0	ROOT	19	injections
2	of	of	B-PP	IN	O	1	NMOD	0
3	HAH-cortisol	HAH-cortisol	B-NP	NN	O	2	PMOD	0
4	into	into	B-PP	IN	O	1	NMOD	0
5	mice	mouse	B-NP	NNS	O	4	PMOD	0
6	bearing	bear	B-VP	VBG	O	5	NMOD	0
7	s.c	s.c	B-NP	NN	O	6	OBJ	0
8	.	.	O	.	O	1	P	0

1	sponge	sponge	B-NP	NN	O	2	NMOD	0
2	implants	implant	I-NP	NNS	O	3	SUB	0
3	retarded	retard	B-VP	VBD	O	0	ROOT	18	retarded
4	vascularization	vascularization	B-NP	NN	O	3	OBJ	3	vascularization
5	of	of	B-PP	IN	O	4	NMOD	0
6	the	the	B-NP	DT	O	7	NMOD	0
7	sponge	sponge	I-NP	NN	O	5	PMOD	0
8	,	,	O	,	O	15	P	0
9	and	and	O	CC	O	15	VMOD	0
10	injections	injection	B-NP	NNS	O	15	SUB	0
11	directly	directly	B-ADVP	RB	O	12	PMOD	0
12	into	into	B-PP	IN	O	10	NMOD	0
13	the	the	B-NP	DT	O	14	NMOD	0
14	sponge	sponge	I-NP	NN	O	12	PMOD	0
15	abolished	abolish	B-VP	VBD	O	3	VMOD	18	abolished
16	vascularization	vascularization	B-NP	NN	O	15	OBJ	3	vascularization
17	for	for	B-PP	IN	O	16	NMOD	0
18	as	as	B-ADVP	RB	O	17	PMOD	0
19	long	long	I-ADVP	RB	O	18	AMOD	0
20	as	as	B-SBAR	IN	O	18	AMOD	0
21	the	the	B-NP	DT	O	22	NMOD	0
22	injections	injection	I-NP	NNS	O	23	SUB	0
23	were	be	B-VP	VBD	O	20	SBAR	0
24	continued	continue	I-VP	VBN	O	23	VC	0
25	.	.	O	.	O	3	P	0

1	Daily	Daily	B-NP	JJ	O	2	NMOD	0
2	i.v	i.v	I-NP	NN	O	0	ROOT	0
3	.	.	O	.	O	2	P	0

1	injections	injection	B-NP	NNS	O	10	SUB	19	injections
2	of	of	B-PP	IN	O	1	NMOD	0
3	HAH-cortisol	HAH-cortisol	B-NP	NN	O	2	PMOD	0
4	at	at	B-PP	IN	O	1	NMOD	0
5	doses	dose	B-NP	NNS	O	4	PMOD	0
6	causing	cause	B-VP	VBG	O	5	NMOD	0
7	no	no	B-NP	DT	O	9	NMOD	0
8	apparent	apparent	I-NP	JJ	O	9	NMOD	0
9	toxicity	toxicity	I-NP	NN	O	6	OBJ	0
10	retarded	retard	B-VP	VBD	O	0	ROOT	18	retarded
11	the	the	B-NP	DT	O	12	NMOD	0
12	growth	growth	I-NP	NN	O	10	OBJ	4	growth
13	of	of	B-PP	IN	O	12	NMOD	0
14	solid	solid	B-NP	JJ	O	15	NMOD	0
15	s.c	s.c	I-NP	NN	O	13	PMOD	0
16	.	.	O	.	O	10	P	0

1	Lewis	Lewis	B-NP	NNP	O	3	NMOD	0
2	lung	lung	I-NP	NN	O	3	NMOD	0
3	carcinomas	carcinoma	I-NP	NNS	O	0	ROOT	0
4	in	in	B-PP	IN	O	3	NMOD	0
5	mice	mouse	B-NP	NNS	O	4	PMOD	0
6	by	by	B-PP	IN	O	3	NMOD	0
7	up	up	B-NP	RB	O	10	NMOD	0
8	to	to	I-NP	TO	O	7	AMOD	0
9	65	65	I-NP	CD	O	7	AMOD	0
10	%	%	I-NP	NN	O	6	PMOD	0
11	.	.	O	.	O	3	P	0

1	In	In	B-PP	IN	O	17	VMOD	0
2	all	all	B-NP	DT	O	1	PMOD	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	these	these	B-NP	DT	O	5	NMOD	0
5	assays	assay	I-NP	NNS	O	3	PMOD	0
6	,	,	O	,	O	17	P	0
7	equivalent	equivalent	B-NP	JJ	O	8	NMOD	0
8	treatments	treatment	I-NP	NNS	O	17	SUB	19	treatments
9	with	with	B-PP	IN	O	8	NMOD	0
10	a	a	B-NP	DT	O	11	NMOD	0
11	mixture	mixture	I-NP	NN	O	9	PMOD	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	the	the	B-NP	DT	O	16	NMOD	0
14	HAH	HAH	I-NP	NN	B-protein	16	NMOD	0
15	plus	plus	I-NP	CC	O	16	NMOD	0
16	cortisol	cortisol	I-NP	NN	O	12	PMOD	0
17	was	be	B-VP	VBD	O	0	ROOT	0
18	significantly	significantly	B-ADJP	RB	O	17	PRD	0
19	less	less	I-ADJP	RBR	O	18	AMOD	0
20	effective	effective	I-ADJP	JJ	O	18	AMOD	0
21	.	.	O	.	O	17	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	antiproliferative	antiproliferative	I-NP	JJ	O	3	NMOD	1	proliferative
3	effect	effect	I-NP	NN	O	9	SUB	18	effect
4	of	of	B-PP	IN	O	3	NMOD	0
5	HAH-cortisol	HAH-cortisol	B-NP	NN	O	4	PMOD	0
6	on	on	B-PP	IN	O	3	NMOD	0
7	endothelial	endothelial	B-NP	JJ	B-cell_type	8	NMOD	0
8	cells	cell	I-NP	NNS	I-cell_type	6	PMOD	0
9	appeared	appear	B-VP	VBD	O	0	ROOT	0
10	independent	independent	B-ADJP	JJ	O	9	PRD	0
11	of	of	B-PP	IN	O	10	AMOD	0
12	the	the	B-NP	DT	O	14	NMOD	0
13	glucocorticoid	glucocorticoid	I-NP	NN	O	14	NMOD	0
14	activity	activity	I-NP	NN	O	11	PMOD	0
15	of	of	B-PP	IN	O	14	NMOD	0
16	the	the	B-NP	DT	O	17	NMOD	0
17	steroid	steroid	I-NP	NN	O	15	PMOD	0
18	since	since	B-SBAR	IN	O	9	VMOD	0
19	HAH	HAH	B-NP	NN	O	20	SUB	0
20	conjugated	conjugate	B-VP	VBD	O	18	SBAR	19	conjugated
21	to	to	B-PP	TO	O	20	VMOD	0
22	5	5	B-NP	CD	O	32	NMOD	0
23	beta-pregnane-3	beta-pregnane-3	I-NP	NN	O	32	NMOD	0
24	alpha	alpha	B-NP	SYM	O	32	NMOD	0
25	,	,	O	,	O	32	P	0
26	17	17	B-NP	CD	O	32	NMOD	0
27	alpha	alpha	B-NP	SYM	O	32	NMOD	0
28	,	,	O	,	O	32	P	0
29	21-triol-20-one	21-triol-20-one	B-NP	NN	O	32	NMOD	0
30	,	,	O	,	O	32	P	0
31	a	a	B-NP	DT	O	32	NMOD	0
32	steroid	steroid	I-NP	NN	O	21	PMOD	0
33	lacking	lack	B-VP	VBG	O	32	NMOD	0
34	glucocorticoid	glucocorticoid	B-NP	NN	O	37	NMOD	0
35	or	or	I-NP	CC	O	37	NMOD	0
36	mineralocorticoid	mineralocorticoid	I-NP	NN	O	37	NMOD	0
37	activity	activity	I-NP	NN	O	33	OBJ	0
38	,	,	O	,	O	20	P	0
39	was	be	B-VP	VBD	O	20	VMOD	0
40	even	even	B-ADJP	RB	O	39	PRD	0
41	more	more	I-ADJP	RBR	O	40	AMOD	0
42	effective	effective	I-ADJP	JJ	O	40	AMOD	0
43	at	at	B-PP	IN	O	40	AMOD	0
44	inhibiting	inhibit	B-VP	VBG	O	43	PMOD	0
45	DNA	DNA	B-NP	NN	O	46	NMOD	0
46	synthesis	synthesis	I-NP	NN	O	44	OBJ	0
47	by	by	B-PP	IN	O	46	NMOD	0
48	murine	murine	B-NP	JJ	B-cell_type	52	NMOD	0
49	pulmonary	pulmonary	I-NP	JJ	I-cell_type	52	NMOD	0
50	capillary	capillary	I-NP	JJ	I-cell_type	52	NMOD	0
51	endothelial	endothelial	I-NP	JJ	I-cell_type	52	NMOD	0
52	cells	cell	I-NP	NNS	I-cell_type	47	PMOD	0
53	than	than	B-SBAR	IN	O	44	VMOD	0
54	was	be	B-VP	VBD	O	53	SBAR	0
55	HAH-cortisol	HAH-cortisol	B-NP	NN	O	54	PRD	0
56	.	.	O	.	O	9	P	0

1	In	In	B-PP	IN	O	5	VMOD	0
2	conclusion	conclusion	B-NP	NN	O	1	PMOD	0
3	,	,	O	,	O	5	P	0
4	HAH-cortisol	HAH-cortisol	B-NP	NN	O	5	SUB	0
5	represents	represent	B-VP	VBZ	O	0	ROOT	0
6	the	the	B-NP	DT	O	7	NMOD	0
7	prototype	prototype	I-NP	NN	O	5	OBJ	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	a	a	B-NP	DT	O	11	NMOD	0
10	new	new	I-NP	JJ	O	11	NMOD	0
11	class	class	I-NP	NN	O	8	PMOD	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	angiogenesis	angiogenesis	B-NP	NN	O	14	NMOD	3	angiogenesis
14	inhibitors	inhibitor	I-NP	NNS	O	12	PMOD	0
15	for	for	B-PP	IN	O	7	NMOD	0
16	the	the	B-NP	DT	O	17	NMOD	0
17	treatment	treatment	I-NP	NN	O	15	PMOD	19	treatment
18	of	of	B-PP	IN	O	17	NMOD	0
19	cancer	cancer	B-NP	NN	O	23	NMOD	0
20	and	and	O	CC	O	23	NMOD	0
21	other	other	B-NP	JJ	O	23	NMOD	0
22	angiogenic	angiogenic	I-NP	JJ	O	23	NMOD	3	angiogenic
23	diseases	disease	I-NP	NNS	O	18	PMOD	0
24	.	.	O	.	O	5	P	0

